Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18148221 | 0.86 | SLC40A1 (0.34) | SLC40A1MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL18147974 | 0.82 | CNKSR1 (0.42) | SLC40A1MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL18147970 | 0.82 | CNKSR1 (0.42) | SLC40A1MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL18148058 | 0.72 | PTGS1 (0.40) | MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL7081766 | 0.58 | NLRP3 (0.50) | SLC40A1MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL27807352 | 0.56 | L3MBTL1 (0.48) | MEN1ALDH1A1KMT2A | |
| SCHEMBL175216 | 0.55 | FDPS (0.43) | ALDH1A1PKM | |
| SCHEMBL8229998 | 0.55 | SLC40A1 (0.46) | SLC40A1MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL18710026 | 0.55 | SLC40A1 (0.46) | SLC40A1MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL11037434 | 0.54 | SLC40A1 (0.54) | SLC40A1MEN1ALDH1A1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | CNKSR1, CAMKK1, CNR1 | SLC40A1 4767/4885MEN1 2360/4885ALDH1A1 4731/4885 |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CNR1 | SLC40A1 4767/4885MEN1 2360/4885ALDH1A1 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.